Forte Biosciences Inc
NASDAQ:FBRX

Watchlist Manager
Forte Biosciences Inc Logo
Forte Biosciences Inc
NASDAQ:FBRX
Watchlist
Price: 22.56 USD -4.45% Market Closed
Market Cap: 282.7m USD

Forte Biosciences Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Forte Biosciences Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Forte Biosciences Inc
NASDAQ:FBRX
Operating Income
-$53.4m
CAGR 3-Years
-63%
CAGR 5-Years
-1%
CAGR 10-Years
-10%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Forte Biosciences Inc
Glance View

Market Cap
282.5m USD
Industry
Biotechnology

Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.

FBRX Intrinsic Value
Not Available

See Also

What is Forte Biosciences Inc's Operating Income?
Operating Income
-53.4m USD

Based on the financial report for Sep 30, 2025, Forte Biosciences Inc's Operating Income amounts to -53.4m USD.

What is Forte Biosciences Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-10%

Over the last year, the Operating Income growth was -49%. The average annual Operating Income growth rates for Forte Biosciences Inc have been -63% over the past three years , -1% over the past five years , and -10% over the past ten years .

Back to Top